

Tresiba[®] (insulin degludec) – First-time authorized brand alternative

- On September 8, 2022, [Novo Nordisk announced](#) the launch of an authorized brand alternative (ABA) of its Tresiba (insulin degludec) injection.
 - The insulin degludec ABA will be available later this fall in vials and prefilled pens (FlexTouch[®]).
- Tresiba is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.